Manufacturing: Page 14
-
Sponsored by MilliporeSigma
Product characterization: Reveal your molecule earlier, faster, and with accuracy
Partnering for product characterization can streamline drug development and create efficiencies in moving from concept to clinic.
Oct. 15, 2019 -
Sponsored by MilliporeSigma
Product characterization: Reveal your molecule earlier, faster, and with accuracy
Partnering for product characterization can streamline drug development and create efficiencies in moving from concept to clinic.
Oct. 15, 2019 -
Gene therapy biotechs caught in manufacturing crunch
Rising demand for contract manufacturing services could push companies to invest more in their own capabilities despite the high cost.
By Ned Pagliarulo • Updated Oct. 11, 2019 -
Premier joins forces with Amphastar on 7 drugs in short supply
The agreement is another example of how healthcare companies are searching for new ways to address drug shortages.
By Kristin Jensen • Oct. 10, 2019 -
Cellectis turns to Lonza to manufacture cancer cell therapies
Lonza's Netherlands facility will complement Cellectis' own sites in development, the French biopharma said.
By Kristin Jensen • Oct. 3, 2019 -
FDA calls generic Zantac carcinogen levels 'unacceptable,' but pushes back against lab claims
Regulators say the third-party lab isn't using a suitable method in tests showing even higher levels of NDMA, a probable human carcinogen.
By Kristin Jensen • Oct. 3, 2019 -
After fanfare, Civica Rx delivers its 1st drugs
A Utah hospital was the first recipient of a medication produced by the hospital coalition, which set out last year to provide generics typically in short supply.
By Samantha Liss • Oct. 2, 2019 -
CVS suspends Zantac sales, as recalls widen over carcinogen fears
Citing an "abundance of caution," CVS announced it would halt sales of the commonly used heartburn drug until further notice.
By Andrew Dunn • Sept. 30, 2019 -
Novartis recall of generic Zantac expands to US
British drugmaker GlaxoSmithKline, meanwhile, said it would halt distribution of Zantac product in countries where it sells the heartburn drug.
By Kristin Jensen • Sept. 26, 2019 -
GSK to spend $120M on new manufacturing hub for drug pipeline
The investment is part of nearly $400 million the British pharma has spent since 2017 to build out its vaccine and specialty drug production in the U.S.
By Kristin Jensen • Sept. 26, 2019 -
FDA
Novartis stops distributing generic Zantac as carcinogen concerns rise
While the FDA continues to investigate NDMA contamination in generic Zantac, Canadian regulators moved to halt distribution of the heartburn drug.
By Kristin Jensen • Sept. 19, 2019 -
Private equity firm to buy Sanofi's oldest plant in India
Advent International snagged Sanofi's generics unit for $2 billion last year. Now, that unit is ready to acquire the Indian plant for about $37 million.
By Kristin Jensen • Sept. 12, 2019 -
Mallinckrodt selling CDMO business for up to $250M
The deal gives needed cash to Mallinckrodt, which is under pressure for its role in the opioid epidemic, and provides another example of private equity's interest in contract manufacturing.
By Kristin Jensen • Sept. 12, 2019 -
Latest Civica Rx pact aims to ease shortage of emergency medicine
The Intermountain-led coalition of providers inked a deal with Exela for supplying sodium bicarbonate to member hospitals.
By Samantha Liss • Sept. 10, 2019 -
Sponsored by Millipore Sigma
How to get upstream right the first time while accelerating the time from DNA to material?
BioReliance's mini-pool approach enables efficient selection of high producing cell lines and accelerates upstream processes.
Sept. 6, 2019 -
Celltrion taps Lonza to produce some of its Remicade biosimilar
Under the deal, Lonza will make Remsima drug substance at its commercial facility in Singapore to cover European and North American markets.
By Jacob Bell • Sept. 5, 2019 -
Novo Nordisk Foundation makes green grant to Danish-US university collaboration
The $27 million grant will fund a five-year program in biopharmaceutical manufacturing, run in partnership by NC State and the Technical University of Denmark.
By Jonathan Gardner • Sept. 5, 2019 -
Elizabeth Regan/BioPharma Dive
Catalent's legacy business outshined by acquisitions
The recent additions of Cook Pharmica, Juniper and Paragon are driving more revenue growth than the contract manufacturer's base business.
By Jacob Bell • Aug. 29, 2019 -
Biopharma jobs boom in Massachusetts, though challenges still exist
Many more jobs have opened up in R&D than in manufacturing, which saw growth of just 1% between 2017 and 2018.
By Jacob Bell • Aug. 27, 2019 -
HHS to fund further manufacturing of Merck Ebola vaccine
An outbreak of the virus in the Democratic Republic of the Congo is now the second largest on record, making vaccination programs more critical.
By Ned Pagliarulo • Aug. 22, 2019 -
As supply shortages persist, ADMA relaunches immune globulin drug
Three of the plasma-derived therapies are currently in shortage, according to the FDA, putting pressure on hospitals and infusion centers.
By Ned Pagliarulo • Aug. 22, 2019 -
Pfizer injects $500M more into gene therapy manufacturing
The money is going toward a North Carolina plant that will make the inactivated viruses used to deliver gene therapies and employ 300 staff.
By Jacob Bell • Aug. 21, 2019 -
Technology permeates the cold chain warehouse — but has its limits
At DHL's cold storage facility in Chicago, technologies such as RFID are designed to withstand cold temperatures and help monitor shipments, including those for life sciences companies.
By Jen A. Miller • Aug. 13, 2019 -
Nektar battered over manufacturing issues and Bristol-Myers pullback
A study of skin, kidney and bladder cancer found disease progressed faster after patients received inactive doses of a Nektar drug paired with Opdivo.
By Jonathan Gardner • Aug. 9, 2019 -
PE firm to buy Cambrex for $2.4B amid flurry of CDMO acquisitions
Permira’s planned deal marks the third in the space topping $1 billion this year.
By Kristin Jensen • Aug. 7, 2019
Previous
